Genes Reveal Kidney Cancer’s Risk of Recurrence

ReachMD Healthcare Image


Studying the mutations in kidney cancer after surgery could help to better predict the risk of the disease coming back, according to the latest results of a decade-long international study.

The research, undertaken by a team of 44 researchers at 23 institutions across Europe and Canada, including McGill University, is the largest to link the genetic changes that occur in kidney cancer to patient outcomes.

More than 400,000 people are diagnosed with kidney cancer each year globally, including 8,100 in Canada and 81,800 in the United States. “Our research shows that it may be possible to improve the way we determine risk in each patient by looking at the genetic mutations present in their cancer,” says Yasser Riazalhosseini, Assistant Professor of Human Genetics, and Head of Cancer Genomics at the Victor Phillip Dahdaleh Institute of Genomic Medicine at McGill University.

“Mutation analysis using DNA sequencing is already being used to help patients with other types of cancer and could be readily applied to patients with kidney cancer,” he adds.

The study published today by the University of Leeds and McGill University, looked at changes in the DNA of more than 900 of kidney cancer samples, and identified four groups of patients based on the presence of mutations in 12 specific genes within the DNA. The team also looked at whether the cancer had recurred in each of these patients.

The researchers found some 91 per cent of patients in one mutation group remained disease-free five years after surgery, meaning patients in this group may potentially avoid unnecessary treatment. Meanwhile, the percentage of patients in a different mutation group who remained disease-free at five years was much lower, at 51 per cent. This identified them as requiring more aggressive treatment.

Preventing cancer recurrence

Currently, doctors assess the risk of kidney cancer returning by looking at features like the size of the tumor and how aggressive it appears under a microscope. With up to 30 per cent of localized kidney cancers returning after surgery, more accurate methods of assessing this risk are needed, meaning patients who do not need further treatment can be spared it, say the researchers.

“Accurately determining the risk of cancer recurrence is very important. It helps us identify how often patients need to be seen by their doctors and decide who to treat with immunotherapy. This treatment has recently been shown to reduce the chances of the cancer coming back but can cause side-effects. The danger currently is that some patients may be over-treated, so being able to better identify patients at low risk of recurrence is important,” says Naveen Vasudev, Associate Professor and Honorary Consultant in Medical Oncology at the Leeds Institute of Medical Research.

Personalizing risk prediction and treatment

The results of this research mean that tumor DNA sequencing may provide a more effective way to predict a patient’s risk of kidney cancer recurrence. This could, in the future, lead to more personalized treatment for kidney cancer.

“Development of new treatments for kidney cancer has lagged behind other cancers and we largely continue to adopt a ‘one size fits all’ approach,” says Vasudev.

“Genomics – the study of genes and how they interact with each other – is a key area of development in patient care. Here we show how genomics might be applied to patients with kidney cancer, potentially creating more personalized treatment options for thousands of patients each year,” he says.

About the study

Application of genomic sequencing to refine patient stratification for adjuvant therapy in renal cell carcinoma” by Naveen Vasudev et al. was published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

The research has leveraged the extensive collaborative network of the Cancer Genomics of the Kidney (CAGEKID) consortium, which was initiated in 2010 by Dr. Mark Lathrop, currently Scientific Director of Victor Phillip Dahdaleh Institute of Genomic Medicine at McGill University, in the context of International Cancer Genome Consortium (ICGC). The study was co-led by Dr Naveen Vasudev, Associate Professor and Honorary Consultant in Medical Oncology in the Leeds Institute of Medical Research, and Dr Yasser Riazalhosseini, Assistant Professor of Human Genetics, and Head of Cancer Genomics at Victor Phillip Dahdaleh Institute of Genomic Medicine at McGill University.

About McGill University

Founded in Montreal, Quebec, in 1821, McGill University is Canada’s top ranked medical doctoral university. McGill is consistently ranked as one of the top universities, both nationally and internationally. It is a world-renowned institution of higher learning with research activities spanning three campuses, 11 faculties, 13 professional schools, 300 programs of study and over 39,000 students, including more than 10,400 graduate students. McGill attracts students from over 150 countries around the world, its 12,000 international students making up 30% of the student body. Over half of McGill students claim a first language other than English, including approximately 20% of our students who say French is their mother tongue.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free